Water retention

An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative

Retrieved on: 
Tuesday, August 15, 2023

Moreover, Dupixent continues to enjoy a unique position as the only advanced treatment for EoE.

Key Points: 
  • Moreover, Dupixent continues to enjoy a unique position as the only advanced treatment for EoE.
  • Consequently, an unlikely candidate has emerged as the next significant advancement in EoE, potentially landing the coveted second-to-market position.
  • APT-1011, a reformulation of the commonly used EoE treatment fluticasone, achieved significant improvements in both histologic and symptomatic endpoints.
  • Speaking with physicians in depth, Spherix explored the benefits and implications of APT-1011 when compared to the gold standard EoE treatment, Dupixent.

Bunge Launches Program to Drive Regenerative Agriculture in Brazil

Retrieved on: 
Monday, May 1, 2023

Bunge announced the creation of a regenerative agriculture program to support Brazilian farmers in the transition to low-carbon agriculture, offering technical support, tools, products, and services, while supporting global efforts to minimize greenhouse gas (GHG) emissions.

Key Points: 
  • Bunge announced the creation of a regenerative agriculture program to support Brazilian farmers in the transition to low-carbon agriculture, offering technical support, tools, products, and services, while supporting global efforts to minimize greenhouse gas (GHG) emissions.
  • The regenerative agriculture program already has dozens of large-scale farmers signed up, covering roughly 250,000 hectares (~615,000 acres) of land in the Brazilian States of Bahia, Maranhão, Mato Grosso, Paraná, Piauí, and Tocantins.
  • To implement the program, Bunge has convened a team of partners who share tools and expertise with participants to support to the adoption of regenerative practices in their operations, with a focus on monitoring and measuring progress and monetizing sustainable agriculture.
  • "We are convinced that the program will further strengthen Bunge’s connection with farmers,” says Rossano de Angelis Jr, Vice President of Agribusiness in South America, Bunge.

The dirt on soil health: The Weston Family Soil Health Initiative awards $10 million in funding to support the adoption of soil health improving practices on Canada’s farmlands

Retrieved on: 
Monday, February 13, 2023

However, there is good news and it’s right under our feet.

Key Points: 
  • However, there is good news and it’s right under our feet.
  • Research shows that improving soil health on agricultural lands offers one of the largest and most immediate opportunities to improve biodiversity and mitigate climate change in Canada.
  • Today, to support this effort, the Weston Family Foundation, through the Weston Family Soil Health Initiative, is announcing $10 million in funding to help promote more adaptive and resilient agricultural lands.
  • “We have an opportunity to address the gap in Canada by helping to mobilize the sector to increase the adoption of soil health improving practices.”

Global Regenerative Agriculture Markets, 2022-2027 - Increasing Demand for Sustainably Sourced Food & Beverage Products to Propel Market Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023

According to this report, the global regenerative agriculture market size is estimated to be valued at USD 8.7 Billion in 2022.

Key Points: 
  • According to this report, the global regenerative agriculture market size is estimated to be valued at USD 8.7 Billion in 2022.
  • Environmental sustainability and natural inputs are prioritized in regenerative agriculture, which is anticipated to drive the regenerative agriculture market.
  • By practice, agroforestry is forecasted to gain the largest market share in the regenerative agriculture market during the study period.
  • The regenerative agriculture market in North America is driven by the presence of customers willing to pay higher amounts for sustainable sourced food & beverage products.

Biostimulants Market worth $6.2 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 5, 2023

CHICAGO, Jan. 5, 2023 /PRNewswire/ -- The Biostimulants Market is estimated to be valued at USD 3.5 billion in 2022.

Key Points: 
  • CHICAGO, Jan. 5, 2023 /PRNewswire/ -- The Biostimulants Market is estimated to be valued at USD 3.5 billion in 2022.
  • It is projected to reach USD 6.2 billion by 2027, recording a CAGR of 11.8% from 2022 to 2027 according to a new report by MarketsandMarkets™.
  • The ease of application of foliar spray is one of the key drivers for growth in the market.
  • The key players in this market include BASF SE (Germany), UPL Limited (India), Adama Ltd. (Israel) and FMC Corporation (US).

Biostimulants Market worth $6.2 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 5, 2023

CHICAGO, Jan. 5, 2023 /PRNewswire/ -- The Biostimulants Market is estimated to be valued at USD 3.5 billion in 2022.

Key Points: 
  • CHICAGO, Jan. 5, 2023 /PRNewswire/ -- The Biostimulants Market is estimated to be valued at USD 3.5 billion in 2022.
  • It is projected to reach USD 6.2 billion by 2027, recording a CAGR of 11.8% from 2022 to 2027 according to a new report by MarketsandMarkets™.
  • The ease of application of foliar spray is one of the key drivers for growth in the market.
  • The key players in this market include BASF SE (Germany), UPL Limited (India), Adama Ltd. (Israel) and FMC Corporation (US).

Regenerative Agriculture Market by Practice, Application and Region - Global Forecast to 2027

Retrieved on: 
Wednesday, December 21, 2022

Key Points: 
  • Environmental sustainability and natural inputs are prioritized in regenerative agriculture, which is anticipated to drive the regenerative agriculture market.
  • By practice, agroforestry is forecasted to gain the largest market share in the regenerative agriculture market during the study period.
  • By application, soil and crop management is anticipated to acquire the largest market share in the regenerative agriculture market during the review period.
  • The North America region is projected to account for the largest market share in the regenerative agriculture market during the forecast period.

Agriculture and Farming Pioneers Unite to Launch Regenified at ExpoWest 2022

Retrieved on: 
Tuesday, March 8, 2022

ANAHEIM, Calif., March 8, 2022 /PRNewswire-PRWeb/ -- Regenified , the agricultural company focused on regenerative soil verification, has launched today at the ExpoWest conference in Anaheim, California.

Key Points: 
  • ANAHEIM, Calif., March 8, 2022 /PRNewswire-PRWeb/ -- Regenified , the agricultural company focused on regenerative soil verification, has launched today at the ExpoWest conference in Anaheim, California.
  • Regenerative farming produces high-quality food that tastes great and is better for consumers.
  • Led by a team of regenerative farming pioneers, experts, and innovators, Regenified has relationships with consultants who advise on over 30 million acres of farms and ranch lands alongside food manufacturers and retailers to promote and verify regenerative farming practices.
  • Founded in 2021 by a team of regenerative farming pioneers, experts, and innovators, Regenified works with farmers and ranchers alongside food manufacturers and retailers to promote regenerative agricultural practices through the Regenified seal.

Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection

Retrieved on: 
Tuesday, November 16, 2021

Shreehas Tambe, dCEO, Biocon Biologics said: "At Biocon Biologics we are committed to expanding access to high-quality, affordable biologics to patients worldwide.

Key Points: 
  • Shreehas Tambe, dCEO, Biocon Biologics said: "At Biocon Biologics we are committed to expanding access to high-quality, affordable biologics to patients worldwide.
  • SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris andBiocon Biologics, are now available in the U.S. market.
  • The currently marketed non-interchangeable SEMGLEE (insulin glargine) is anticipated to be phased out by the end of the 2021 calendar year.
  • Viatris and Biocon Biologics have an exclusive collaboration for the development, manufacturing and commercialization of a broad portfolio of biosimilars and insulin analogs.

Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary

Retrieved on: 
Wednesday, October 20, 2021

As part of this commitment, Viatris will soon commercialize two versions of this landmark insulin glargine injection, the first-ever interchangeable biosimilar approved by the U.S. Food and Drug Administration (FDA): Semglee (insulin glargine-yfgn) injection, a branded interchangeable product, and Insulin Glargine (insulin glargine-yfgn) Injection, an authorized interchangeable biosimilar.

Key Points: 
  • As part of this commitment, Viatris will soon commercialize two versions of this landmark insulin glargine injection, the first-ever interchangeable biosimilar approved by the U.S. Food and Drug Administration (FDA): Semglee (insulin glargine-yfgn) injection, a branded interchangeable product, and Insulin Glargine (insulin glargine-yfgn) Injection, an authorized interchangeable biosimilar.
  • This dual product approach is intended to ensure that this historic interchangeable biosimilar insulin can reach as many patients as possible regardless of financial circumstances, insurance or channel.
  • "The inclusion of our interchangeable biosimilar on Express Scripts' National Preferred Formulary (NPF)is an important milestone to help increase access to insulin for those living with diabetes across the U.S.," said Tony Mauro, President, Developed Markets for Viatris.
  • The Express Scripts formulary change including coverage of Semglee (insulin glargine-yfgn) on its NPF will occur effective January 1, 2022.